Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody and use as a tumor vaccine and for targeting applications
AssigneeImmunomedics, Inc.
InventorsShui-on Leung, Michele J. Losman, Hans Hansen
Life of this patent
Estimating the term…
Abstract
A humanized form of an anti-idotype antibody to CEA, e.g., hW12, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idotype also can be used as an immunogenic vaccine.
Claims12
An anti-idiotype antibody or an antigen binding fragment thereof, which specifically binds to the idiotype region of an anti-CEA monoclonal antibody, MN-14, wherein said anti-idiotypic antibody comprises the rat anti-idiotypic antibody (rWI2) light chain variable region comprising SEQ ID NO:22 and heavy chain variable region comprising SEQ ID NO:
- 18 derived from a rat antibody and constant regions selected from human antibody sequences.
A humanized anti-idiotype antibody or an antigen binding fragment thereof which specifically binds the idiotype region of an anti-CEA CEA monoclonal antibody, MN-14, wherein said humanized anti-idiotypic antibody comprises rat anti-idiotypic antibody (rWI2) CDRs, wherein the CDRs of the light chain variable region comprises:
- the CDR-1 sequence, SEQ ID NO:
- 4, RASQDIGNYLR,
- the CDR-2 sequence, SEQ ID NO:
- 5, GATNLAA, and
- the CDR-3 sequence, SEQ ID NO:
- 6, LHHSEYPYT;
- and, wherein the CDRs of the heavy chain variable region comprises:
- the CDR-1 sequence, SEQ ID NO:
- 1, NYWMT,
- the CDR-2 sequence, SEQ ID NO:
- 2, SITSTGGTYHAESVKG, and
- the CDR-3 sequence, SEQ ID NO:
- 3, DDYGGQSTYVMDA;
- and humanized framework regions.
Dependencies are inferred from the claim text.